Journal of the National Cancer Center最新文献

{"title":"Burden of malignant mesothelioma in China during 1990–2019 and the projections through 2029","authors":"","doi":"10.1016/j.jncc.2024.05.003","DOIUrl":"10.1016/j.jncc.2024.05.003","url":null,"abstract":"<div><h3>Objective</h3><p>To provide the most up-to-date data on the burden of malignant mesothelioma (MM) and the projections through 2029 in China.</p></div><div><h3>Methods</h3><p>Data on patients diagnosed with MM from China during 1990–2019 were obtained from the Global Burden of Disease (GBD) 2019 database, including annual cases and deaths data and age-standardized rates of incidence, mortality, and disability-adjusted life-years (DALYs) associated with MM among different age groups. Temporal trends during 1990–2019 were analyzed by the Joinpoint regression models using 95% confidence interval (CI), while the projections through 2029 were calculated by the Bayesian age-period-cohort model. Data on the production and consumption of asbestos in China were obtained from the United States Geological Survey on Mineral Commodity Summaries during 1996–2023.</p></div><div><h3>Results</h3><p>We observed a significant elevation in incident new cases and deaths over the last 3 decades, increasing from 1193 in 1990 to 2815 in 2019 for incident cases and from 1134 in 1990 to 2773 in 2019 for death cases. We found a roughly 6% increase in the proportion of incident cases for those aged &gt;70 years (30% in 2019 versus 24% in 1990), while for the proportion of deaths similar elevation for those aged &gt;70 years was found. Additionally, men had significantly higher DALYs due to MM across age groups compared with women. Asbestos consumption in China dramatically dropped since 2012 and reached the bottom in 2017 with 230 kilotons. By 2029, the projected age-standardized rate for incidence and mortality is expected to reach 1.2 per million for both.</p></div><div><h3>Conclusion</h3><p>We found, for the first time using GBD data on the Chinese population, that the burden of MM has been significantly increasing in China over the last three decades and will continue to increase in the upcoming decade, suggesting an urgent need for a complete ban on chrysotile asbestos in China.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"4 3","pages":"Pages 214-222"},"PeriodicalIF":7.6,"publicationDate":"2024-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667005424000292/pdfft?md5=1ae76bef0471d1f5a72e72ff1c9c8196&pid=1-s2.0-S2667005424000292-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141050133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nowcasting and forecasting global aging and cancer burden: analysis of data from the GLOBOCAN and Global Burden of Disease Study","authors":"","doi":"10.1016/j.jncc.2024.05.002","DOIUrl":"10.1016/j.jncc.2024.05.002","url":null,"abstract":"<div><h3>Objective</h3><p>To analyze the impact of global population aging on cancer epidemiology, with a focus on the incidence and mortality rates among individuals aged 60 years and above.</p></div><div><h3>Methods</h3><p>We utilized open-source data, retrieving population age estimates from the United Nations Population Division website. The GLOBOCAN 2020 database provided estimates for cancer cases and deaths in 2020 and 2040, while the Global Burden of Disease 2019 database supplied estimates of new cancer cases worldwide from 2000 to 2019. Inclusion criteria considered individuals aged 60 years and over, focusing on the top five deadliest cancers. The cohort-component method was employed for population prediction, with age-specific incidence and mortality rates estimated for 2020 used to forecast the cancer burden.</p></div><div><h3>Results</h3><p>In 2021, the global population aged over 60 years accounted for 13.7%, with Europe/North America and Australia/New Zealand having the highest proportions. The older population is predicted to reach 19.2% by 2040. In 2020, of the 19.3 million new cancer cases worldwide, 64% occurred in individuals aged 60 and above, contributing to 71.3% of cancer-related deaths. The five most common cancer sites were the lung, colorectum, prostate, breast, and stomach. Cancer incidence and deaths are projected to rise significantly among older individuals, reaching 20.7 million new cases and 12.7 million deaths by 2040. Older age, tobacco use, dietary factors, alcohol consumption, and high body mass index (BMI) were identified as major risk factors for various cancers in this demographic.</p></div><div><h3>Conclusions</h3><p>This study reveals a significant rise in cancer incidence and mortality among the elderly due to global population aging. The urgency for targeted interventions in cancer prevention, screening, and treatment for older individuals is emphasized. Despite acknowledged limitations, these findings contribute valuable insights to inform strategies for managing cancer in the elderly amidst evolving demographic trends.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"4 3","pages":"Pages 223-232"},"PeriodicalIF":7.6,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667005424000280/pdfft?md5=339a9c3baceafb0faa17b40049215b8d&pid=1-s2.0-S2667005424000280-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141031293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of overall survival benefit of radiotherapy with progression-free survival after chemotherapy for diffuse large B-cell lymphoma: A systematic review and meta-analysis","authors":"","doi":"10.1016/j.jncc.2024.04.002","DOIUrl":"10.1016/j.jncc.2024.04.002","url":null,"abstract":"<div><h3>Objective</h3><p>To evaluate whether improved progression-free survival (PFS) from radiotherapy (RT) translates into an overall survival (OS) benefit for diffuse large B-cell lymphoma (DLBCL).</p></div><div><h3>Methods</h3><p>A systematic literature search identified randomized controlled trials (RCTs) and retrospective studies that compared combined-modality therapy (CMT) with chemotherapy (CT) alone. Weighted regression analyses were used to estimate the correlation between OS and PFS benefits. Cohen's kappa statistic assessed the consistency between DLBCL risk-models and PFS patterns. Furthermore, the benefit trend of RT was analyzed by fitting a linear regression model to the pooled hazard ratio (HR) according to the PFS patterns.</p></div><div><h3>Results</h3><p>For both 7 RCTs and 52 retrospective studies, correlations were found between PFS HR (HR_PFS) and OS HR (HR_OS) at trial level (<em>r</em> = 0.639–0.876), and between PFS and OS rates at treatment-arm level, regardless of CT regimens (<em>r</em> = 0.882–0.964). Incorporating RT into CT increased about 18% of PFS, and revealed a different OS benefit profile. Patients were stratified into four CT-generated PFS patterns (&gt;80%, &gt;60–80%, &gt;40–60%, and ≤40%), which was consistent with risk-stratified subgroups (kappa &gt; 0.6). Absolute gain in OS from RT ranged from ≤5% at PFS &gt;80% to about 21% at PFS ≤40%, with pooled HR_OS from 0.70 (95% CI, 0.51–0.97) to 0.48 (95% CI, 0.36–0.63) after rituximab-based CT. The OS benefit of RT was predominant in intermediate- and high-risk patients with PFS ≤ 80%.</p></div><div><h3>Conclusion</h3><p>We demonstrated a varied OS benefit profile of RT to inform treatment decisions and clinical trial design.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"4 3","pages":"Pages 249-259"},"PeriodicalIF":7.6,"publicationDate":"2024-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667005424000231/pdfft?md5=6ecbbe0e8123ee6ac7c34f77b7ccb7f5&pid=1-s2.0-S2667005424000231-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140764999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Linking fatty liver diseases to hepatocellular carcinoma by hepatic stellate cells","authors":"Liang'en Chen ,&nbsp;Xiangshi Ye ,&nbsp;Lixian Yang ,&nbsp;Jiangsha Zhao ,&nbsp;Jia You ,&nbsp;Yuxiong Feng","doi":"10.1016/j.jncc.2024.01.002","DOIUrl":"10.1016/j.jncc.2024.01.002","url":null,"abstract":"<div><p>Hepatic stellate cells (HSCs), a distinct category of non-parenchymal cells in the liver, are critical for liver homeostasis. In healthy livers, HSCs remain non-proliferative and quiescent. However, under conditions of acute or chronic liver damage, HSCs are activated and participate in the progression and regulation of liver diseases such as liver fibrosis, cirrhosis, and liver cancer. Fatty liver diseases (FLD), including nonalcoholic (NAFLD) and alcohol-related (ALD), are common chronic inflammatory conditions of the liver. These diseases, often resulting from multiple metabolic disorders, can progress through a sequence of inflammation, fibrosis, and ultimately, cancer. In this review, we focused on the activation and regulatory mechanism of HSCs in the context of FLD. We summarized the molecular pathways of activated HSCs (aHSCs) in mediating FLD and their role in promoting liver tumor development from the perspectives of cell proliferation, invasion, metastasis, angiogenesis, immunosuppression, and chemo-resistance. We aimed to offer an in-depth discussion on the reciprocal regulatory interactions between FLD and HSC activation, providing new insights for researchers in this field.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"4 1","pages":"Pages 25-35"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667005424000024/pdfft?md5=bb74d72c9a0f791f190599cb50c79c6d&pid=1-s2.0-S2667005424000024-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139639159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of radiotherapy in patients with refractory Hodgkin's lymphoma after treatment with brentuximab vedotin and/or immune checkpoint inhibitors","authors":"Ruizhi Zhao ,&nbsp;Han Shao ,&nbsp;Guiqing Shi ,&nbsp;Yanyan Qiu ,&nbsp;Tianlan Tang ,&nbsp;Yuping Lin ,&nbsp;Silin Chen ,&nbsp;Cheng Huang ,&nbsp;Siqin Liao ,&nbsp;Jinhua Chen ,&nbsp;Haiying Fu ,&nbsp;Jianzhi Liu ,&nbsp;Benhua Xu ,&nbsp;Tingbo Liu ,&nbsp;Yujing Zhang ,&nbsp;Yong Yang","doi":"10.1016/j.jncc.2023.11.001","DOIUrl":"10.1016/j.jncc.2023.11.001","url":null,"abstract":"<div><h3>Background</h3><p>Approximately 10%–30% of patients with Hodgkin's lymphoma (HL) experience relapse or refractory (R/R) disease after first-line standard therapy. Brentuximab vedotin (BV) and immune checkpoint inhibitors (ICIs) have important roles in the salvage treatment of R/R HL. However, subsequent treatment for HL refractory to BV and/or ICI treatment is challenging.</p></div><div><h3>Methods</h3><p>We retrospectively analyzed patients in two institutions who had R/R HL, experienced BV or ICI treatment failure, and received radiotherapy (RT) thereafter. The overall response rate (ORR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS) were analyzed.</p></div><div><h3>Results</h3><p>Overall, 19 patients were enrolled. First-line systemic therapy comprised doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD, 84.2%); AVD plus ICIs (10.5%); and bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP, 5.3%). After first-line therapy, 15 (78.9%) and four patients (21.1%) had refractory disease and relapsed, respectively. After R/R HL diagnosis, six (31.6%), two (10.5%), and 11 (57.9%) patients received BV and ICIs concurrently, BV monotherapy, and ICI monotherapy, respectively. All patients received intensity-modulated RT (<em>n</em> = 12, 63.2%) or volumetric modulated arc therapy (VMAT; <em>n</em> = 7, 36.8%). The ORR as well as the complete response (CR) rate was 100%; the median DOR to RT was 17.2 months (range, 7.9–46.7 months). Two patients showed progression outside the radiation field; one patient had extensive in-field, out-of-field, nodal, and extranodal relapse. With a median follow-up time of 16.2 months (range, 9.2–23.2 months), the 1-year PFS and OS were 84.4% and 100%, respectively. PFS was associated with extranodal involvement (<em>P</em> = 0.019) and gross tumor volume (<em>P</em> = 0.044). All patients tolerated RT well without adverse events of grade ≥ 3.</p></div><div><h3>Conclusion</h3><p>RT is effective and safe for treating HL refractory to BV or ICIs and has the potential to be part of a comprehensive strategy for HL.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"4 1","pages":"Pages 86-92"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667005423000790/pdfft?md5=5ed10c1d2418af0cb19e4f5fcaa00df9&pid=1-s2.0-S2667005423000790-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135614133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug-tolerant persister cancer cells","authors":"Pengliang Wang ,&nbsp;Bin Ke ,&nbsp;Gang Ma","doi":"10.1016/j.jncc.2023.12.002","DOIUrl":"10.1016/j.jncc.2023.12.002","url":null,"abstract":"","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"4 1","pages":"Pages 1-5"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667005423000844/pdfft?md5=59574b79966cb188e3fcb885b16f71f3&pid=1-s2.0-S2667005423000844-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139018710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The breast cancer tumor microenvironment and precision medicine: immunogenicity and conditions favoring response to immunotherapy","authors":"Andrea Nicolini ,&nbsp;Paola Ferrari ,&nbsp;Roberto Silvestri ,&nbsp;Federica Gemignani","doi":"10.1016/j.jncc.2024.01.004","DOIUrl":"10.1016/j.jncc.2024.01.004","url":null,"abstract":"<div><p>Some main recent researches that have dissected tumor microenvironment (TME) by imaging mass cytometry (IMC) in different subtypes of primary breast cancer samples were considered. The many phenotypic variants, clusters of epithelial tumor and immune cells, their structural features as well as the main genetic aberrations, sub-clonal heterogeneity and their systematic classification also have been examined. Mutational evolution has been assessed in primary and metastatic breast cancer samples. Overall, based on these findings the current concept of precision medicine is questioned and challenged by alternative therapeutic strategies. In the last two decades, immunotherapy as a powerful and harmless tool to fight cancer has received huge attention. Thus, the tumor immune microenvironment (TIME) composition, its prognostic role for clinical course as well as a novel definition of immunogenicity in breast cancer are proposed. Investigational clinical trials carried out by us and other findings suggest that G0-G1 state induced in endocrine-dependent metastatic breast cancer is more suitable for successful immune manipulation. Residual micro-metastatic disease seems to be another specific condition that can significantly favor the immune response in breast and other solid tumors.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"4 1","pages":"Pages 14-24"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667005424000048/pdfft?md5=250175de16a639d9a4e99861ab76dd40&pid=1-s2.0-S2667005424000048-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139636455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer survival analysis on population-based cancer registry data in Zhejiang Province, China (2018–2019)","authors":"Huizhang Li ,&nbsp;Youqing Wang ,&nbsp;Weiwei Gong ,&nbsp;Chen Zhu ,&nbsp;Le Wang ,&nbsp;Yaoyao Chen ,&nbsp;Lingbin Du ,&nbsp;Xiangdong Cheng","doi":"10.1016/j.jncc.2023.12.003","DOIUrl":"10.1016/j.jncc.2023.12.003","url":null,"abstract":"<div><h3>Objective</h3><p>This is a comprehensive overview of long-term cancer survival in Zhejiang Province, China. Hybrid analysis, a combination of cohort and period analysis, has been proposed to derive up-to-date cancer survival estimates. Using this approach, we aimed to timely and accurately analyze the 5-year relative survival (RS) and net survival (NS) in cancer registries of Zhejiang Province, China.</p></div><div><h3>Methods</h3><p>A total of 255,725 new cancer cases diagnosed during 2013–2017 were included in 14 cancer registries in Zhejiang Province, China, with a follow-up on vital status until the end of 2019. The hybrid analysis was used to calculate the 5-year RS and 5-year NS during 2018–2019 for overall and stratifications by sex, cancer type, region, and age at diagnosis.</p></div><div><h3>Results</h3><p>During 2018–2019, the age-standardized 5-year RS and NS for overall cancer in Zhejiang was 47.5% and 48.6%, respectively. The age-standardized 5-year RS for cancers of women (55.4%) was higher than that of men (40.0%), and the rate of urban areas (49.7%) was higher than that of rural areas (43.1%). The 5-year RS declined along with age, from 84.4% for ages &lt;45 years to 23.7% for ages &gt;74 years. Our results of the RS and NS showed the similar trend and no significant difference. The top five cancers with top age-standardized 5-year RS were thyroid cancer (96.0%), breast cancer (84.3%), testicular cancer (79.9%), prostate cancer (77.2%), and bladder cancer (70.6%), and the five cancers with the lowest age-standardized 5-year RS were pancreatic cancer (6.0%), liver cancer (15.6%), gallbladder cancer (17.1%), esophageal cancer (22.7%), and leukemia (31.0%).</p></div><div><h3>Conclusions</h3><p>We reported the most up-to-date 5-year cancer RS and NS in Zhejiang Province, China for the first time, and found that the 5-year survival for cancer patients in Zhejiang during 2018–2019 was relatively high. The population-based cancer registries are recognized as key policy tools that can be used to evaluate both the impact of cancer prevention strategies and the effectiveness of health systems.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"4 1","pages":"Pages 54-62"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667005423000856/pdfft?md5=4397fd19f81b652927e9919540cb1f3a&pid=1-s2.0-S2667005423000856-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139193402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How to properly evaluate cardiac vagal tone in oncology studies: a state-of-the-art review","authors":"Pierrick Martinez ,&nbsp;Marilyne Grinand ,&nbsp;Saïda Cheggour ,&nbsp;Jérôme Taieb ,&nbsp;Géraud Gourjon","doi":"10.1016/j.jncc.2024.02.002","DOIUrl":"10.1016/j.jncc.2024.02.002","url":null,"abstract":"<div><p>Heart rate variability (HRV) analysis provides an assessment of cardiac vagal tone and consequently global cardiac health as well as systemic condition. In systemic diseases such as cancer and during treatments that affect the whole body, like chemotherapy, the vagus nerve activity is low and deregulated. Some studies focus on using HRV to predict mortality in oncology. However, in cancer patients, systemic alterations substantially increase artifacts during HRV measurement, especially atrial ectopic beats. Moreover, HRV may be altered by various factors (duration and time of measurement, breathing, drugs, and other confounding factors) that alter each metric in different ways. The Standard Deviation of all Normal to Normal intervals (SDNN) is the most commonly used metric to evaluate HRV in oncology, but it does not appear to be specific to the cardiac vagal tone. Thus, cardiac vagal activity diagnosis and vital prognosis of cancer patients can be biased. Our review presents the main HRV metrics that can be currently used in oncology studies and their links with vagus nerve and cancer. We present the influence of external factors and the required duration and time of measurement. Considering all these parameters, this review proposes seven key points for an assessment of HRV and cardiac vagal tone in patients with cancer.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"4 1","pages":"Pages 36-46"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667005424000085/pdfft?md5=d8f5eb1248bc2daacfe614e365bf228b&pid=1-s2.0-S2667005424000085-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139826778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chinese quality control indices for standardized diagnosis and treatment of renal cancer (2022 edition)","authors":"Lin Yao ,&nbsp;Yicong Du ,&nbsp;Wen Dong ,&nbsp;Xianshu Gao ,&nbsp;Jun Guo ,&nbsp;Jianxing Qiu ,&nbsp;Qiang Wei ,&nbsp;Shikai Wu ,&nbsp;Dingwei Ye ,&nbsp;Wei Yu ,&nbsp;Hao Zeng ,&nbsp;Qian Zhang ,&nbsp;Yong Zhang ,&nbsp;Zhiling Zhang ,&nbsp;Fangjian Zhou ,&nbsp;Wenjing Yang ,&nbsp;Hui Wang ,&nbsp;Xu Zhang ,&nbsp;Zhisong He ,&nbsp;for Renal Cancer Quality Control Experts Committee of National Cancer Quality Control Center, National Cancer Center of the People's Republic of China","doi":"10.1016/j.jncc.2023.11.004","DOIUrl":"10.1016/j.jncc.2023.11.004","url":null,"abstract":"<div><p>Renal cancer is one of the most common malignancies of the urinary system, and the number of deaths continues to increase. The standardized management of the diagnosis and treatment of renal cancer is challenging due to the great differences in the diagnosis and treatment of renal cancer in different regions. The Renal Cancer Expert Committee of the National Cancer Quality Control Center (NCQCC) identified a lack of authoritative quality control standards as an opportunity to utilize its multidisciplinary membership to improve the standardized diagnosis and treatment of renal cancer. The Renal Cancer Expert Committee of the NCQCC aims to promote quality control and national standardization, uniformity, and normalization of renal cancer diagnosis and treatment, which ultimately improved the survival rate and quality of life of renal cancer patients. A panel of experts with renal cancer surgery, renal cancer medicine, medical imaging, pathology and radiotherapy were drawn together and determined the quality control standards for the standardized diagnosis and treatment of renal cancer. The Indices includes 20 items that cover all key areas in the diagnosis and treatment of renal cancer, such as standard diagnosis, surgery treatment, systemic treatment, and prognostic evaluation.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"4 1","pages":"Pages 6-13"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667005423000820/pdfft?md5=20ee7619013802ca7233b6847fdc8dc5&pid=1-s2.0-S2667005423000820-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138624611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}